EMA panel rejects Biogen Alzheimer's drug

By Manas Mishra
Updated November 18 2021 - 1:20am, first published 1:14am
A European Medicines Agency panel has voted down Biogen's application for Alzheimer's drug Aduhelm.
A European Medicines Agency panel has voted down Biogen's application for Alzheimer's drug Aduhelm.

A European regulatory panel has voted against approval of Biogen Inc's Alzheimer's disease drug, in a possible blow to the prospects of the drug already grappling with a slow rollout in the United States.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options